Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 46 to 60 of 204 results for dementia

  1. Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (TA217)

    Evidence-based recommendations on donepezil (Aricept), galantamine (Reminyl), rivastigmine (Exelon) and memantine (Ebixa) for treating Alzheimer's disease in adults.

    Technology appraisal guidance
    Last updated
    20 June 2018
    View recommendations

    Sections for TA217

  2. How strong are the associations between hearing and visual loss, and sleep patterns and positive and negative health outcomes, in particular the development of dementia, disability and frailty? What are the most effective and cost-effective interventions to protect hearing and vision and improve sleep and what is their effect on the development of dementia, disability and frailty?

    positive and negative health outcomes, in particular the development of dementia, disability and frailty? What are the most effective...

    Research recommendation
    Published
    9 December 2015

  3. Anticholinergic burden:- Does actively reducing anticholinergic burden in people living with dementia improve cognitive outcomes compared with usual care?

    burden:- Does actively reducing anticholinergic burden in people living with dementia improve cognitive outcomes compared with usual...

    Research recommendation
    Published
    10 December 2018

  4. Falls (QS86)

    This quality standard covers prevention of falls and assessment after a fall in people who are living in the community, in a residential care setting or staying in hospital and are:

    Quality standard
    Last updated
    29 April 2025
    View quality statements

    Sections for QS86

  5. Semaglutide for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID6635]

    Awaiting development Reference number: GID-TA11847 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Blarcamesine for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [TSID12157]

    Awaiting development Reference number: GID-TA11717 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Acute kidney injury (QS76)

    This quality standard covers preventing, detecting and managing acute kidney injury in adults, young people and children. It describes high-quality care in priority areas for improvement.

    Quality standard
    Last updated
    23 March 2023
    View quality statements

    Sections for QS76

  8. Case management:- What is the effectiveness and cost effectiveness of high-intensity case management compared with usual care on quality of life (for the person living with dementia and for their carers) and the timing of entry to long-term care?

    compared with usual care on quality of life (for the person living with dementia and for their carers) and the timing of entry to...

    Research recommendation
    Published
    10 December 2018

  9. Cataracts in adults: management (NG77)

    This guideline covers managing cataracts in adults aged 18 and over. It aims to improve care before, during and after cataract surgery by optimising service organisation, referral and surgical management, and reducing complications. It further aims to improve the availability of information for people with cataracts before, during and after cataract surgery.

    NICE guideline
    Published
    26 October 2017
    View recommendations

    Sections for NG77

  10. Care of dying adults in the last days of life (NG31)

    This guideline covers the clinical care of adults (18 years and over) who are dying during the last 2 to 3 days of life. It aims to improve end of life care for people in their last days of life by communicating respectfully and involving them, and the people important to them, in decisions and by maintaining their comfort and dignity. The guideline covers how to manage common symptoms without causing unacceptable side effects and maintain hydration in the last days of life.

    NICE guideline
    Published
    16 December 2015
    View recommendations

    Sections for NG31

  11. What is the prevalence of risk and protective factors in mid-life for the development of dementia, disability and frailty, and what are the longitudinal relationships between them? Are dose–response relationships evident and how strong are these? Which factors are independent and which mediate others?

    prevalence of risk and protective factors in mid-life for the development of dementia, disability and frailty, and what are the...

    Research recommendation
    Published
    9 December 2015

  12. Transition between inpatient hospital settings and community or care home settings for adults with social care needs (QS136)

    This quality standard covers admissions into, and discharge from, inpatient hospital settings for adults (aged 18 years and over) with social care needs. It describes high-quality care in priority areas for improvement.

    Quality standard
    Published
    1 December 2016
    View quality statements

    Sections for QS136

  13. What are the most effective and cost-effective population-level measures to help people in mid-life maintain or adopt healthy behaviours and build up resilience to dementia, disability and frailty? What are the best methods for evaluating their effect? How do these measures affect health inequalities?

    mid-life maintain or adopt healthy behaviours and build up resilience to dementia, disability and frailty? What are the best methods for...

    Research recommendation
    Published
    9 December 2015

  14. Diagnostics advisory committee members

    Biographies for all current members of the diagnostics advisory committee.

  15. Diagnostics advisory committee members

    Biographies for all current members of the diagnostics advisory committee.